{
    "title": "110_s2029",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Physician Payments Sunshine Act of \n2007''.\n\nSEC. 2. QUARTERLY TRANSPARENCY REPORTS FROM MANUFACTURERS OF COVERED \n              DRUGS, DEVICES, OR MEDICAL SUPPLIES UNDER MEDICARE, \n              MEDICAID, OR SCHIP.\n\n    Part A of title XI of the Social Security Act (42 U.S.C. 1301 et \nseq.) is amended by inserting after section 1128F the following new \nsection:\n\n``SEC. 1128G. QUARTERLY TRANSPARENCY REPORTS FROM MANUFACTURERS OF \n              COVERED DRUGS, DEVICES, OR MEDICAL SUPPLIES UNDER \n              MEDICARE, MEDICAID, OR SCHIP.\n\n    ``(a) Reporting of Payments or Other Transfer of Value.--On January \n1, 2008, and the first day of each fiscal year quarter beginning \nthereafter, each manufacturer of a covered drug, device, or medical \nsupply who provides a payment or other transfer of value, directly, \nindirectly, or through an agent, subsidiary, or other third party, to a \nphysician, or to an entity that a physician is employed by, has tenure \nwith, or has an ownership interest in, shall submit to the Secretary, \nin such electronic form as the Secretary shall require, the following:\n            ``(1) The name of the physician, and if a payment or other \n        transfer of value was provided to an entity that the physician \n        is employed by, has tenure with, or has an ownership interest \n        in, the entity.\n            ``(2) The address of--\n                    ``(A) the physician's office; and\n                    ``(B) in the case of an entity required to be named \n                under paragraph (1), the primary place of business or \n                headquarters for the entity.\n            ``(3) The facility with which the physician is affiliated, \n        if any.\n            ``(4) The value of the payment or other transfer of value.\n            ``(5) The date on which the payment or other transfer of \n        value was provided.\n            ``(6) A description of the nature of the payment or other \n        transfer of value, indicated (as appropriate for all that \n        apply) as--\n                    ``(A) compensation;\n                    ``(B) food, entertainment, or gifts;\n                    ``(C) trips or travel;\n                    ``(D) a product or other item provided for less \n                than market value;\n                    ``(E) participation in a medical conference, \n                continuing medical education, or other educational or \n                informational program or seminar, provision of \n                materials related to such a conference or educational \n                or informational program or seminar, or remuneration \n                for promoting or participating in such a conference or \n                educational or informational program or seminar;\n                    ``(F) product rebates or discounts;\n                    ``(G) consulting fees or honoraria; or\n                    ``(H) any other economic benefit, as defined by the \n                Secretary.\n            ``(7) The medical issue or condition addressed, if any, \n        that was the basis for the payment or transfer.\n    ``(b) Annual Summary Report.--Each manufacturer of a covered drug, \ndevice, or medical supply that is required to submit information under \nsubsection (a) during a year shall submit a report to the Secretary not \nlater than December 31 of the year that summarizes, in such electronic \nform as the Secretary shall specify, each submission of information \nunder subsection (a) made by the manufacturer during the year.\n    ``(c) Penalty for Noncompliance.--Any manufacturer of a covered \ndrug, device, or medical supply that fails to submit information \nrequired under subsection (a) or (b) in accordance with regulations \npromulgated to carry out such subsection, shall be subject to a civil \nmoney penalty of not less than $10,000, but not more than $100,000, for \neach such failure. Such penalty shall be imposed and collected in the \nsame manner as civil money penalties under subsection (a) of section \n1128A are imposed and collected under that section.\n    ``(d) Public Availability.--Not later than June 1, 2008, the \nSecretary shall establish procedures to ensure that the information \nreported under subsection (a) and the summary reports submitted under \nsubsection (b) are readily accessible to the public through an Internet \nwebsite that is easily searchable, downloadable, and understandable.\n    ``(e) Report to Congress.--Not later than April 1 of each year \nbeginning with 2009, the Secretary shall submit to Congress a report \nthat includes the following:\n            ``(1) The information submitted under subsections (a) and \n        (b) during the preceding year, aggregated for each manufacturer \n        of a covered drug, device, or medical supply that submitted \n        such information during such year.\n            ``(2) A description of any enforcement actions taken to \n        carry out this section, including any penalties imposed under \n        subsection (c), during the preceding year.\n    ``(f) Definitions.--In this section:\n            ``(1) Covered drug, device, or medical supply.--The term \n        `covered drug, device, or medical supply' means any drug, \n        biological product, device, or medical supply for which payment \n        is available under title XVIII or a State plan under title XIX \n        or XXI (or a waiver of such a plan).\n            ``(2) Manufacturer of a covered drug, device, or medical \n        supply.--The term `manufacturer of a covered drug, device, or \n        medical supply' means any entity with annual gross revenues \n        that exceed $100,000,000, which is engaged in--\n                    ``(A) the production, preparation, propagation, \n                compounding, conversion, or processing of a covered \n                drug, device, or medical supply; or\n                    ``(B) the packaging, repackaging, labeling, \n                relabeling, or distribution of a covered drug, device, \n                or medical supply.\n            ``(3) Payment or other transfer of value.--\n                    ``(A) In general.--The term `payment or other \n                transfer of value' means a transfer of anything of \n                value that exceeds $25, and includes any compensation, \n                gift, honorarium, speaking fee, consulting fee, travel, \n                discount, cash rebate, or services.\n                    ``(B) Exclusions.--Such term does not include the \n                following:\n                            ``(i) Product samples that are intended for \n                        patients.\n                            ``(ii) A payment or other transfer of value \n                        made for the general funding of a clinical \n                        trial.\n                            ``(iii) A transfer of anything of value to \n                        a physician when the physician is a patient and \n                        not acting in his or her professional capacity.\n            ``(4) Physician.--The term `physician' has the meaning \n        given that term in section 1861(r).''."
}